A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

NCT04778800 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

NSCLC
Brain Metastases
Leptomeningeal Metastasis

Interventions

DRUG: almonertinib
DRUG: LM-first line treatment
DRUG: LM-second line treatment

Sponsor

Henan Cancer Hospital